Clopidogrel DURA

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
10-07-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
10-07-2015
Public Assessment Report Public Assessment Report (PAR)
10-07-2015

Active ingredient:

clopidogrel (as hydrochloride)

Available from:

Mylan dura GmbH

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Антитромботични агенти

Therapeutic area:

Peripheral Vascular Diseases; Stroke; Myocardial Infarction

Therapeutic indications:

Клопидогрел е показан за възрастни за профилактика на атеротромботических събития:пациенти, страдащи инфарктом инфаркт (от няколко дни до по-малко от 35 дни), исхемичен инсулт (от 7 дни до по-малко от 6 месеца) или установена заболяване на периферните артерии.

Product summary:

Revision: 6

Authorization status:

Отменено

Authorization date:

2009-07-21

Patient Information leaflet

                                23
B. ЛИСТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
24
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
CLOPIDOGREL DURA 75 MG ФИЛМИРАНИ ТАБЛЕТКИ
клопидогрел (сlopidogrel)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да имате
нужда да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лек
арство е предписано единствено и
лично на Вас. Не го преотстъпвайте на
други
хора. То може да им навреди,
независимо, че признаците на тяхното
заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
лекарствени реакции включително
неописани в тази
листовка нежелани реакции, уведомете
Вашия лекар или фармацевт. Вижте точка
4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Clopidogrel dura и за
какво се използва
2.
Какво трябва да знаете, преди да
приемете Clopidogrel dura
3.
Как да приемате Clopidogrel dura
4.
Възможни нежелани реакции
5.
Как да съхранявате Clopidogrel dura
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА CLOPIDOGREL
DURA И ЗА КАКВО СЕ ИЗПОЛЗВА
Clopidogrel dura, съ
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Clopidogrel dura 75 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка филмирана таблетка съдържа 75 mg
клопидогрел (като хидрохлорид).
Помощно вещество с известно действие:
Всяка филмирана таблетка съдържа 13 mg
хидрогенирано рициново масло.
За пълният списък на помощните
вещества, вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка.
Розова, кръгла и леко изпъкнала
филмирана таблетка.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
_Предпазване от атеротромботични
инциденти _
Клопидогрел е показан при :

Възрастни пациенти с анамнеза за
миокарден инфаркт (от няколко дни до 35
дни),
исхемичен ин
султ (от 7-мия ден до 6-тия месец) или
установено периферно артериално
заболяване.
За повече информация, моля вижте точка
5.1.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
-
Възрастни и хора в старческа възраст
Клопидогрел трябва да се прилага като
единична дневна доза от 75 mg.
Ако е проп
усната доза:
-
В рамките на по-малко от 12 часа след
редовно определеното време:
пациентите
трябва да прием
                                
                                Read the complete document

Similar products

Active ingredient clopidogrel (as hydrochloride)

clopidogrel (as hydrochloride)

ATC code B01AC04

B01AC04

Marketed by Mylan dura GmbH

Mylan dura GmbH

INN (International Name) clopidogrel

clopidogrel

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 10-07-2015
Summary of Product characteristics Summary of Product characteristics Spanish 10-07-2015
Public Assessment Report Public Assessment Report Spanish 10-07-2015
Patient Information leaflet Patient Information leaflet Czech 10-07-2015
Summary of Product characteristics Summary of Product characteristics Czech 10-07-2015
Public Assessment Report Public Assessment Report Czech 10-07-2015
Patient Information leaflet Patient Information leaflet Danish 10-07-2015
Summary of Product characteristics Summary of Product characteristics Danish 10-07-2015
Public Assessment Report Public Assessment Report Danish 10-07-2015
Patient Information leaflet Patient Information leaflet German 10-07-2015
Summary of Product characteristics Summary of Product characteristics German 10-07-2015
Public Assessment Report Public Assessment Report German 10-07-2015
Patient Information leaflet Patient Information leaflet Estonian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Estonian 10-07-2015
Public Assessment Report Public Assessment Report Estonian 10-07-2015
Patient Information leaflet Patient Information leaflet Greek 10-07-2015
Summary of Product characteristics Summary of Product characteristics Greek 10-07-2015
Public Assessment Report Public Assessment Report Greek 10-07-2015
Patient Information leaflet Patient Information leaflet English 10-07-2015
Summary of Product characteristics Summary of Product characteristics English 10-07-2015
Public Assessment Report Public Assessment Report English 10-07-2015
Patient Information leaflet Patient Information leaflet French 10-07-2015
Summary of Product characteristics Summary of Product characteristics French 10-07-2015
Public Assessment Report Public Assessment Report French 10-07-2015
Patient Information leaflet Patient Information leaflet Italian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Italian 10-07-2015
Public Assessment Report Public Assessment Report Italian 10-07-2015
Patient Information leaflet Patient Information leaflet Latvian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Latvian 10-07-2015
Public Assessment Report Public Assessment Report Latvian 10-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-07-2015
Public Assessment Report Public Assessment Report Lithuanian 10-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 10-07-2015
Public Assessment Report Public Assessment Report Hungarian 10-07-2015
Patient Information leaflet Patient Information leaflet Maltese 10-07-2015
Summary of Product characteristics Summary of Product characteristics Maltese 10-07-2015
Public Assessment Report Public Assessment Report Maltese 10-07-2015
Patient Information leaflet Patient Information leaflet Dutch 10-07-2015
Summary of Product characteristics Summary of Product characteristics Dutch 10-07-2015
Public Assessment Report Public Assessment Report Dutch 10-07-2015
Patient Information leaflet Patient Information leaflet Polish 10-07-2015
Summary of Product characteristics Summary of Product characteristics Polish 10-07-2015
Public Assessment Report Public Assessment Report Polish 10-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 10-07-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 10-07-2015
Public Assessment Report Public Assessment Report Portuguese 10-07-2015
Patient Information leaflet Patient Information leaflet Romanian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Romanian 10-07-2015
Public Assessment Report Public Assessment Report Romanian 10-07-2015
Patient Information leaflet Patient Information leaflet Slovak 10-07-2015
Summary of Product characteristics Summary of Product characteristics Slovak 10-07-2015
Public Assessment Report Public Assessment Report Slovak 10-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 10-07-2015
Public Assessment Report Public Assessment Report Slovenian 10-07-2015
Patient Information leaflet Patient Information leaflet Finnish 10-07-2015
Summary of Product characteristics Summary of Product characteristics Finnish 10-07-2015
Public Assessment Report Public Assessment Report Finnish 10-07-2015
Patient Information leaflet Patient Information leaflet Swedish 10-07-2015
Summary of Product characteristics Summary of Product characteristics Swedish 10-07-2015
Public Assessment Report Public Assessment Report Swedish 10-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 10-07-2015
Patient Information leaflet Patient Information leaflet Icelandic 10-07-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 10-07-2015
Patient Information leaflet Patient Information leaflet Croatian 10-07-2015
Summary of Product characteristics Summary of Product characteristics Croatian 10-07-2015

Search alerts related to this product

Alerts Clopidogrel DURA

Clopidogrel DURA

View documents history

Documents history Documents history

Clopidogrel DURA